In brief: Psiron, pSivida, Meditech Research, Optiscan Imaging

By Ruth Beran
Thursday, 16 June, 2005

Greg Williams is Psiron's (ASC:PSX) new chief financial officer, a position he commenced on June 14. He has four years experience as CFO at AstraZeneca Australia as well as with smaller Australian technology companies.

pSivida (ASX:PSD, NASDAQ:PSDV, Xetra:PSI) has been granted its first Korean patent covering the electronic-based properties of biosilicon in the stimulaton of orthopaedic tissue repair and re-engineering where scaffolds are required to support new bone growth. The technology also has application for treatment of fractures that do not heal and in management and monitoring of reconstructive orthopaedic or implant surgery.

Meditech Research (ASX:MTR) has appointed Dr Julian Clark as non-executive director to replace Assoc Prof Tracey Brown who will step down to focus on her executive management role as research director. Clark is currently head of business development at the Walter and Eliza Hall Institute for Medical Research in Melbourne and director of his own management consultancy.

Optiscan Imaging (ASX:OIL) has received a Commercial Ready Grant worth a $1.9 million over the next three years for the development of a multiphoton microscope in the form of a miniaturised handheld probe.

Related News

mRNA successfully delivered through blood–brain barrier

Getting mRNA into the brain could allow scientists to instruct brain cells to produce therapeutic...

Biological computer could revolutionise medical sciences

The CL1 is a commercial biological computer which fuses lab-cultivated neurons from human stem...

Genetic risk of schizophrenia impacts men and women differently

Men tend to present different clinical symptoms from women, poorer premorbid functioning and...


  • All content Copyright © 2025 Westwick-Farrow Pty Ltd